Department of Cellular and Integrative Physiology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, USA.
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
Basic Res Cardiol. 2017 Sep 30;112(6):65. doi: 10.1007/s00395-017-0654-x.
This study was designed to identify mechanisms responsible for coronary vasodilation in response to progressive decreases in hematocrit. Isovolemic hemodilution was produced in open-chest, anesthetized swine via concurrent removal of 500 ml of arterial blood and the addition of 500 ml of 37 °C saline or synthetic plasma expander (Hespan, 6% hetastarch in 0.9% sodium chloride). Progressive hemodilution with Hespan resulted in an increase in coronary flow from 0.39 ± 0.05 to 1.63 ± 0.16 ml/min/g (P < 0.001) as hematocrit was reduced from 32 ± 1 to 10 ± 1% (P < 0.001). Overall, coronary flow corresponded with the level of myocardial oxygen consumption, was dependent on arterial pressures ≥ ~ 60 mmHg, and occurred with little/no change in coronary venous PO. Anemic coronary vasodilation was unaffected by the inhibition of nitric oxide synthase (L-NAME: 25 mg/kg iv; P = 0.92) or voltage-dependent K (K ) channels (4-aminopyridine: 0.3 mg/kg iv; P = 0.52). However, administration of the K channel antagonist (glibenclamide: 3.6 mg/kg iv) resulted in an ~ 40% decrease in coronary blood flow (P < 0.001) as hematocrit was reduced to ~ 10%. These reductions in coronary blood flow corresponded with significant reductions in myocardial oxygen delivery at baseline and throughout isovolemic anemia (P < 0.001). These data indicate that vasodilator factors produced in response to isovolemic hemodilution converge on vascular smooth muscle glibenclamide-sensitive (K ) channels to maintain myocardial oxygen delivery and that this response is not dependent on endothelial-derived nitric oxide production or pathways that mediate dilation via K channels.
这项研究旨在确定导致血球比容降低时冠状动脉扩张的机制。通过同时从开胸麻醉猪中取出 500ml 动脉血并用 37°C 的盐水或合成血浆扩张剂(Hespan,0.9%氯化钠中的 6%羟乙基淀粉)补充 500ml,进行等容血液稀释。用 Hespan 进行渐进性血液稀释导致冠状动脉流量从 0.39±0.05 增加到 1.63±0.16ml/min/g(P<0.001),而血球比容从 32±1%降低到 10±1%(P<0.001)。总体而言,冠状动脉流量与心肌耗氧量水平相对应,依赖于动脉压≥60mmHg,并在冠状动脉静脉 PO 几乎没有变化的情况下发生。贫血性冠状动脉扩张不受一氧化氮合酶抑制剂(L-NAME:25mg/kg 静脉内;P=0.92)或电压依赖性 K(K )通道抑制剂(4-氨基吡啶:0.3mg/kg 静脉内;P=0.52)的影响。然而,给予 K 通道拮抗剂(格列本脲:3.6mg/kg 静脉内)导致冠状动脉血流量下降约 40%(P<0.001),当血球比容降至10%时。这些冠状动脉血流量的减少与基础和等容性贫血期间心肌氧输送的显著减少相对应(P<0.001)。这些数据表明,等容血液稀释引起的血管舒张因子汇聚在血管平滑肌格列本脲敏感(K )通道上,以维持心肌氧输送,并且该反应不依赖于内皮衍生的一氧化氮产生或通过 K 通道介导扩张的途径。